Kevin Rogers
Optometrist · Greenwell Springs, LANPI 1760647960
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,910 of the $7,302 with a category attached, or 80.9%. It is spread thinly across 23 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,284, 2.5 times the $907 reported in 2019. Among optometrist clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 199 payments — averaging $36.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec USA, Inc.$1K
- Alcon$865
- Coopervision Inc.$862
- Optos, Inc.$688
- Oyster Point Pharma, Inc.$669
- Bausch & Lomb Americas Inc.$326
- plus $3K from 17 others
What the payments were for
- Speaking & faculty fees$501%
- Travel & lodging$99214%
- Food & beverage$5,91081%
- Gifts$391%
- Entertainment$3114%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec USA, Inc. | 6 | $1,081 |
| Alcon | 33 | $865 |
| Coopervision Inc. | 12 | $862 |
| Optos, Inc. | 6 | $688 |
| Oyster Point Pharma, Inc. | 42 | $669 |
| Bausch & Lomb Americas Inc. | 12 | $326 |
| Kala Pharmaceuticals, Inc. | 13 | $310 |
| Dompe US, Inc. | 8 | $308 |
| Tarsus Pharmaceuticals, Inc. | 11 | $296 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 15 | $294 |
| Johnson & Johnson Vision Care, Inc. | 3 | $261 |
| Biotissue Holdings Inc. | 9 | $204 |
| AbbVie(2 entities) | 9 | $202 |
| Astellas Pharma US Inc | 2 | $201 |
| Novartis | 4 | $144 |
| Sun Pharmaceutical Industries Inc. | 2 | $142 |
| Glaukos Corporation | 2 | $122 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $118 |
| Maculogix, Inc. | 2 | $90 |
| Eyevance Pharmaceuticals LLC | 2 | $42 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Beaver-visitec International, Inc. | 2 | $20 |
| Harrow Eye, LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MyDay Contact Lens$719
- PANORAMIC OPHTHALMOSCOPE$487
- P200DTx$315
- P200T$315
- P200TE$315
- P200TxE$315
- OCT OPHTHALMOSCOPE$244
- NFC-700$244
- Acuvue$241
- Tecnis Simplicity$235
- CEQUA$125
- TRYPTYR$122
- Oxervate$122
- Izervay$119
- XDEMVY$118
- Tecnis IOL$118
- VERITAS Vision System$118
- KXL System$109
- Photrexa$109
- XIIDRA$100
How this compares
$7,302 in reported general payments places this provider in the 95th percentile of 500 optometrist providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 31 | $31,073 |
| RestasisCyclosporine | 25 | $30,502 |
| LumiganBimatoprost | 57 | $22,929 |
| EysuvisLoteprednol Etabonate | 34 | $16,775 |
| CombiganBrimonidine Tartrate/Timolol | 34 | $14,124 |
| Loteprednol Etabonate | 17 | $7,950 |
| Prednisolone Acetate | 105 | $5,132 |
| Fluorometholone | 51 | $3,941 |
| RhopressaNetarsudil Mesylate | 11 | $3,837 |
| Brimonidine Tartrate | 39 | $2,525 |
| Ketorolac Tromethamine | 23 | $1,112 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 61 | $818 |
| Latanoprost | 76 | $807 |
| Timolol Maleate | 45 | $424 |
| Dorzolamide Hcl | 18 | $424 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $202 | $67,555116 claims |
| Bausch & Lomb Americas Inc.Xiidra | $326 | $31,07331 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $310 | $16,77534 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $294 | $7,95017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 500 optometrist providers in Louisiana.
Other optometrist in Greenwell Springs
- Pamela TheriotShreveport$207K
- Joshua DavidsonGonzales$189K
- Jeffrey WilhiteMarrero$86K
- Christopher WrotenHammond$59K
- James LamarNew Orleans$45K
- John McCallLogansport$32K
- Robert KellyMarrero$26K
- Shane FontenotJennings$23K
- Stephen LewisShreveport$17K
- Breanne McGheeNew Orleans$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.